EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Powering Neurology Drug Development Trials to Reduce False Negative Results

Hiromasa Mori iD, Stig Johan Wiklund iD, Vikram Ramanarayanan iD, Fatta B Nahab iD

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70722 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Hiromasa Mori und 3 weiteren Autor:innen. Beteiligte Einrichtung: EPoC Science Ltd, Oxford, UK. Hauptthemen laut MEDLINE: Drug Development, Research Design, Clinical Trials as Topic, Neurology. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sensitive and reliable measurement of therapeutic outcomes in neurology drug trials remains challenging. Clinical rating scales and their total scores are often considered the gold standard and used as primary efficacy endpoints in studies because of their acceptance by the clinical community and regulators. However, rating scales have limitations when used in drug development, and we hypothesize that their lower statistical power is one possible reason leading to false negative results. This paper proposes a framework to address four systemic components of statistical power—size of the treatment effect, variability, sample size, and statistical threshold—to minimize the odds of observing false negatives, and thereby maximize the odds of trial success. Drawing from the literature and biopharmaceutical anecdotal evidence, we identify key factors that affect each of these power components and assess their influence. We also highlight challenges with rating scale endpoints associated with total scores and large sample sizes. We identify potential causes of rating scale endpoint failure and provide an indication‐agnostic framework for understanding the relationship between clinical rating scale performance and study power. The proposed methods can be applied to both study design and post hoc analysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentResearch DesignClinical Trials as TopicNeurologyNervous System DiseasesHumansFalse Negative ReactionsSample SizeEndpoint Determination

Stichwörter der Autor:innen

CNSPhase IIclinical trialsefficacyfunction testsmathematical modelingneurologyquantitative methodsstatisticsvariability

Autor:innen und Institutionen

  • EPoC Science Ltd, Oxford, UK.
  • Captario AB, Gothenburg, Sweden.
  • Modality.AI Inc, San Francisco, California, USA.
  • University of California San Francisco, San Francisco, California, USA.
  • Neuron23, South San Francisco, California, USA.
  • University of California San Diego, La Jolla, California, USA.

ORCID-Profile: Hiromasa Mori, Stig Johan Wiklund, Vikram Ramanarayanan, Fatta B Nahab

Zitieren

APA

Mori, H., Wiklund, S. J., Ramanarayanan, V., & Nahab, F. B. (2026). Powering Neurology Drug Development Trials to Reduce False Negative Results. Clinical and Translational Science. https://doi.org/10.1111/cts.70722

Vancouver

Mori H, Wiklund SJ, Ramanarayanan V, Nahab FB. Powering Neurology Drug Development Trials to Reduce False Negative Results. Clinical and Translational Science. 2026. doi:10.1111/cts.70722

BibTeX
@article{Mori2026,
  author = {Mori, Hiromasa and Wiklund, Stig Johan and Ramanarayanan, Vikram and Nahab, Fatta B},
  title = {Powering Neurology Drug Development Trials to Reduce False Negative Results},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70722}
}
Kostenlos starten →